Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Global Medical REIT Completes Reverse Stock Split

Global Medical REIT Inc. (NYSE: GMRE) has completed a one-for-five reverse stock split, effective as of September 19, 2025. As a result of the reverse stock split, the company's authorized shares of common stock have been reduced from 500,000,000 shares to 100,000,000 shares, and the number of shares outstanding has decreased from 67,037,048 shares to approximately 13,407,409 shares.

The reverse stock split also resulted in adjustments to the aggregate number of shares authorized for repurchase under the company’s stock repurchase program, the aggregate number of shares issuable under the company’s equity incentive plan, the outstanding equity awards granted under the company’s equity incentive plan, and the outstanding partnership units of Global Medical REIT L.P., the company’s operating partnership.

No fractional shares were issued in connection with the reverse stock split. Instead, stockholders who would have held fractional shares as a result of the reverse stock split are entitled to receive cash in lieu of such fractional shares, based on the closing price of the company's common stock on the NYSE.

Following the reverse stock split, the common stock will begin trading on a reverse split-adjusted basis on the NYSE on September 22, 2025, under the symbol “GMRE” with a new CUSIP number: 37954a303.

Global Medical REIT Inc. is a net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. More information about GMRE can be obtained on its website at www.globalmedicalreit.com. Following these announcements, the company's shares moved -2.59%, and are now trading at a price of $7.53. For the full picture, make sure to review Global Medical REIT's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS